GLP-1 Drugs Revolutionize Obesity Treatment While Raising Questions About Risks and Costs

New research highlights the transformative potential of GLP-1 drugs like Ozempic and tirzepatide, but concerns remain over side effects, affordability, and societal implications.

• GLP-1 receptor agonists, initially developed for diabetes, are now widely used for weight loss, with semaglutide and tirzepatide showing significant results in reducing body weight by up to 20%.
• The drugs are being explored for broader health benefits, including improved cardiovascular and kidney health, reduced inflammation, and potential applications in treating addiction and Alzheimer’s disease.
• Side effects such as nausea, gallbladder issues, and possible links to thyroid tumors have raised concerns, and long-term impacts remain under study.
• The global market for GLP-1 drugs is rapidly expanding, with projections reaching $200 billion by 2031, as pharmaceutical companies develop new formulations and generics to meet demand.
• Critics highlight societal stigma and misconceptions about obesity treatment, urging a shift toward greater understanding of these medications as legitimate tools for managing complex health conditions.

3 Articles

Flow Space The Economist Salon